BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7262161)

  • 41. [Etoposide. A new highly effective cytostatic agent in anaplastic small-cell bronchial carcinoma, other solid tumors and hemoblastoses].
    Goldhirsch A; Joss R; Cavalli F; Sonntag RW; Ryssel HJ; Brunner KW
    Dtsch Med Wochenschr; 1981 Aug; 106(35):1105-9. PubMed ID: 6266800
    [No Abstract]   [Full Text] [Related]  

  • 42. Does etoposide have curative potential?
    Ignoffo RJ
    Clin Pharm; 1983; 2(2):167. PubMed ID: 6309470
    [No Abstract]   [Full Text] [Related]  

  • 43. VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.
    Eagan RT; Carr DT; Frytak S; Rubin J; Lee RE
    Cancer Treat Rep; 1976 Jul; 60(7):949-51. PubMed ID: 64298
    [No Abstract]   [Full Text] [Related]  

  • 44. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
    Lokich J; Corkery J
    Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [A phase II study of oral VP-16 in primary lung cancer].
    Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Slayton RE; Blessing JA; Delgado G
    Cancer Treat Rep; 1982 Aug; 66(8):1669-71. PubMed ID: 7105059
    [No Abstract]   [Full Text] [Related]  

  • 47. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.
    Perry MC; Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
    Cancer Treat Rep; 1976 Sep; 60(9):1247-50. PubMed ID: 797447
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
    Gockerman JP; Bartolucci AA; Nelson MO; Silberman H; Velez-Garcia E; Stein R
    Cancer Treat Rep; 1986 Jun; 70(6):801-2. PubMed ID: 3524829
    [No Abstract]   [Full Text] [Related]  

  • 49. Podophyllotoxin derivative VP 16-213.
    Arnold AM
    Cancer Chemother Pharmacol; 1979; 3(2):71-80. PubMed ID: 389478
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
    Konno K; Nagahama F; Nakai Y; Nakabayashi T; Hiraga Y; Takebe K; Tamura M; Oizumi K; Sato M; Ito T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):931-7. PubMed ID: 3008671
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.
    Anderson G; Payne H
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):21-2. PubMed ID: 3883504
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study.
    Wolff SN; Johnson DH; Hainsworth JD; Greco FA
    J Clin Oncol; 1984 Apr; 2(4):271-4. PubMed ID: 6368760
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II trial of VP-16-213 in advanced ovarian carcinoma.
    Hillcoat BL; Campbell JJ; Pepperell R; Quinn MA; Bishop JF; Day A
    Gynecol Oncol; 1985 Oct; 22(2):162-6. PubMed ID: 4054715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A phase II clinical trial of oral VP 16-213 in advanced non-Hodgkin's lymphoma].
    Nakada H; Ogawa M; Ingaki J; Horikoshi N; Inoue K; Usui N; Adachi K; Tada A; Yamazaki H; Mukaiyama T
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1644-8. PubMed ID: 6476837
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.
    Slayton RE; Creasman WT; Petty W; Bundy B; Blessing JA
    Cancer Treat Rep; 1979; 63(11-12):2089-92. PubMed ID: 526942
    [No Abstract]   [Full Text] [Related]  

  • 56. Combination chemotherapy including VP-16 for poor prognosis germ cell neoplasms.
    Bukowski RM; Smith GW; Montie JE
    Urology; 1988 May; 31(5):403-7. PubMed ID: 2452507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [A phase II trial of etoposide (VP-16) administered intravenously in the treatment of malignant lymphoma and acute leukemia].
    Moriyama Y; Shibata A; Maekawa I; Yoshida Y; Miura A; Wakui A; Kariyone S; Maekawa T; Miura Y; Abe T
    Rinsho Ketsueki; 1985 Nov; 26(11):1774-84. PubMed ID: 3835288
    [No Abstract]   [Full Text] [Related]  

  • 58. Review of etoposide.
    Phillips NC; Lauper RD
    Clin Pharm; 1983; 2(2):112-9. PubMed ID: 6309469
    [No Abstract]   [Full Text] [Related]  

  • 59. A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study.
    Bennett JM; Lymann GH; Cassileth PA; Glick JH; Oken MM
    Am J Clin Oncol; 1984 Oct; 7(5):471-3. PubMed ID: 6594926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Role of VP 16 in the treatment of non-seminomatous germ cell tumors of the testis].
    Bassoulet J; Varette C; Pabot du Chatelard P; Guillemot MC; Joussemet M; Martoia R
    Therapie; 1988; 43(4):279-84. PubMed ID: 2847346
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.